InsiderTrades

Form 4 for ROIV Roivant Sciences Ltd.

Accepted 2023-12-29 00:00:00 ET · period of report 2023-12-27 · accession 0001140361-23-060291 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2023-12-29 2023-12-27 ROIV Kumar Rakhi CAO M - OptEx — +13 192.3K +0.0% —
DT 2023-12-29 2023-12-27 ROIV Kumar Rakhi CAO F - Tax $11.58 -6 192.3K -0.0% -$69.48
DT 2023-12-29 2023-12-27 ROIV Kumar Rakhi CAO M - OptEx $11.50 -1,894 87.1K -2% -$21.8K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares 2023-12-27 M A 13 — 192,295 D — — (F1) Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023.
2 Common Common Shares 2023-12-27 F D 6 $11.58 192,289 D — —
3 Derivative Capped Value Appreciation Rights 2023-12-27 M D 1,894 $11.50 87,126 D — · — to 2026-03-31 13 Common Shares (F3) This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. (F1) Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On December 27, 2023, the hurdle price applicable to 1,894 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 13 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023.